Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Hugging Face released Qwen3.8-27B-pi-adapted, an Apache-2.0 LoRA adapter trained with reinforcement learning for the pi coding agent. It lifts SWE-bench Pro hard-51 pass@1 from 39.2% to 64.7% and ...
In the field of artificial intelligence, machine learning is a branch that uses data and algorithms to imitate human learning. It's an ongoing process in which computers can improve their accuracy ...
Recent insider activity at Recursion Pharmaceuticals consisted of 3 Tax Payment transactions by 3 insiders, totaling $437,905.65 across 111,490 shares on November 16, 2026. Average transaction value ...
At close: 4:00:01 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results